Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2012 · 10-Q
Revenue$498.70M$498.70M−3.4% vs Q3 2011 Net Income$42.63M$42.63M−7.1% vs Q3 2011 EPS Diluted$1.49$1.49−7.5% vs Q3 2011 Gross Profit$273,770,000−7.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$71,342,000+39.5% Free Cash Flowderived$34,673,000+30.9% Margins · derivedGross margin54.9%−2.5 pt vs Q3 2011
Operating margin13.2%−1.1 pt vs Q3 2011
Net margin8.5%−0.3 pt vs Q3 2011
ended Sep 30, 2012 · filed Nov 8, 2012 · 39 d after period end